| Company name | VarmX |
| Year of establishment | 2016 |
| Sector | Life Sciences & Health |
| Website | https://varmx.com/ |
| Status | Follow-up financing picked up |
VarmX
VarmX is a Leiden biotech company developing VMX‑C001, a modified factor X designed to rapidly reverse the effects of FXa‑inhibitor blood thinners in cases of severe bleeding or emergency surgery. A spin‑off from Leiden University Medical Center, it partnered with CSL in 2025 to advance VMX‑C001 toward an expected 2029 market launch.
This investment is managed by
Bart Hoenen, Investment Manger (LEH) at UNIIQ.
